iBio

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins. The company was founded on April 17, 2008 and is headquartered in Bryan, TX.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.

– Board appointments solidify management team to lead iBio's AI-powered biotech strategy – BRYAN, Texas and SAN DIEGO, June 27, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the appointments of Martin Brenner, DVM, Ph.D. as Chief Executive Officer; and Felipe Duran as Chief Financial Officer, effective immediately.

iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company's Next Stage of Growth

CRISPR Therapeutics

Pfizer

Even the most conservative investor hopes to find that one stock that can make them millions. That's why they look at the biotech sector.

3 Millionaire-Maker Biotech Stocks to Buy and Hold Forever

Ibio (NYSEMKT: IBIO ) stock is rising higher on Tuesday as investors react to the company reaching a research collaboration agreement with the NIH. This will see the company teaming up with the NIH's National Institute of Allergy and Infectious Diseases (NIAID).

Why Is iBio (IBIO) Stock Up 16% Today?

– NIH to evaluate iBio's patented AI-driven epitope steering platform for Lassa fever vaccine development –

iBio Forges Research Collaboration with the National Institutes of Health

BRYAN, Texas and SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today that its Interim Chief Executive Officer and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 12:00 p.m. Eastern Time at the New York Hilton Midtown.

iBio to Participate in the JMP Securities Life Sciences Conference

BRYAN, Texas, April 04, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced that a presentation given today by its VP & Head of Machine Learning & Platform Technologies, Matt Greving, Ph.D., during Carterra's "Unlocking High-Throughput Biology and Drug Discovery" symposium in San Diego, CA, revealed the discovery of a panel of CD3 T-cell binding antibodies, representing an important first step for the Company into bispecific immuno-oncology therapies.

iBio Discovers New Panel of CD3 T-Cell Binding Antibodies Using its Patented AI Epitope Steering Platform

– Immuno-oncology candidate discovered using iBio's AI epitope steering platform –

iBio Advances Anti-CCR8 Antibody Program to Preclinical In Vivo Testing

BigBear.ai Holdings

Esperion Therapeutics

Short squeeze penny stocks for your watch list. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? 3 Short Squeeze Stock To Watch

Bed Bath & Beyond

Nabriva Therapeutics

Redfin

Rocket Companies, Inc.

Shift Technologies

Virgin Galactic

Peruse the Internet for investment guidance and you're likely to hear the adage that you shouldn't consider stocks to sell when faced with volatility. Rather, you should buy up assets and securities when there's blood on the streets.

7 Stocks to Sell as Banks Melt Down

Ardelyx

OPKO Health

Rigel Pharmaceuticals

4 biotech penny stocks to watch right now. The post 4 Top Penny Stocks To Watch With Big Biotech News This Quarter appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Watch With Big Biotech News This Quarter

Amarin Corporation Plc

Cidara Therapeutics

Sidus Space

Vascular Biogenics

Penny stocks to watch this week. The post Penny Stocks To Buy: 5 To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy: 5 To Watch Before Next Week

Diversified Healthcare Trust

NGL Energy Partners

Pitney Bowes

4 penny stocks to watch this week. The post 4 Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch With The Stock Market Down Today

Sorrento Therapeutics Inc

How to know when to sell penny stocks The post How to Know When to Sell Penny Stocks  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Know When to Sell Penny Stocks

Ibio (NYSEMKT: IBIO ) stock is rocketing higher on Friday after the biopharmaceutical company announced a new immune-oncology program. According to a press release, iBio has chosen MUC16 as the next focus for its immune-oncology program.

Why Is iBio (IBIO) Stock Up 124% Today?

- Company has directed antibodies against a specific region of MUC16 -

iBio Announces MUC16 as its Latest Immune-Oncology Target Program

Cano Health

Lixte Biotech

Are penny stocks able to provide full time income? The post Can Trading Penny Stocks Be a Full Time Job?

Can Trading Penny Stocks Be a Full Time Job?

BRYAN, Texas, Dec. 09, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the closing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,870,192 shares of common stock and Series B warrants to purchase up to 3,870,192 shares of common stock, at a combined public offering price of $1.04 per share (or pre-funded warrant in lieu thereof) and accompanying warrants, which includes the purchase of additional warrants to purchase up to 1,009,614 shares of common stock purchased pursuant to the partial exercise of the underwriter's option to purchase additional Series A warrants and Series B warrants to purchase. The Series A warrants have an exercise price of $1.04 per share, are exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series B warrants have an exercise price of $1.04 per share, are exercisable immediately upon issuance and will expire twenty-four months from the date of issuance.

iBio Announces Closing of $3.5 Million Underwritten Public Offering

Vinco Ventures

Cenntro Inc

Express

Hyzon Motors

Nikola

Party City Holdco

2022 was a terrible year for the stock market. Fortunately for 2023, news of lower interest rate hikes hints at a new bull market.

7 Penny Stocks to Sell Before They Plunge in 2023

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering of an aggregate of 3,365,385 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,365,385 shares of common stock and Series B warrants to purchase up to 3,365,385 shares of common stock, at a combined public offering price of $1.04 per share (or pre-funded warrants in lieu thereof) and accompanying warrants. The Series A warrants will have an exercise price of $1.04 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance, and the Series B warrants will have an exercise price of $1.04 per share, will be exercisable immediately upon issuance and will expire twenty-four months from the date of issuance. The closing of the offering is expected to occur on or about December 9, 2022, subject to the satisfaction of customary closing conditions.

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

BRYAN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced it intends to offer and sell, subject to market and other conditions, shares of its common stock (or common stock equivalents in lieu thereof) and Series A and Series B warrants to purchase shares of common stock in an underwritten public offering. In connection with the offering, the Company also intends to grant the underwriter a 30-day option to purchase additional shares of its common stock and/or warrants to purchase shares of its common stock at the public offering price, less underwriting discounts and commissions.

iBio Announces Proposed Underwritten Public Offering

BRYAN, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today it will present two posters at the Antibody Engineering & Therapeutics Conference 2022 [AE&T] in San Diego, California, December 4-8. The AE&T Conference features the latest science and research in antibody engineering, design, and selection to drive commercial advances in fields such as immuno-oncology.

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

BRYAN, Texas, Dec. 02, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the Board of Directors (the “Board”) and Thomas F. Isett, the Company's Chief Executive Officer, have agreed that Mr. Isett will resign as a member of the Board and relinquish his duties, rights and obligations as an officer and CEO of the Company, effective immediately. While the Company continues its search for a successor, the leadership team will report to the current Chair of the Board, William (Chip) Clark.

iBio Announces CEO Departure

Electrameccanica

Vroom

Lordstown Motors

It has been a rough year for investors, with the S&P 500 index posting incredible losses not seen in some time. As stocks continue to hover in this fragile market, investors must consider which assets are most valuable in their portfolios.

7 Penny Stocks to Sell Pronto Before a Painful Downturn

OPAL Fuels Inc

Revlon

SkyWater Technology

SurgePays

Virgin Orbit Holdings

Weber

Although contrarianism captured headlines through the first two years of the coronavirus pandemic, it's now time for investors to consider the topic of short-squeeze stocks to sell before traders cash out. Fundamentally, when bears target weak companies, it's usually for glaring vulnerabilities.

7 Short-Squeeze Stocks to Sell Before Traders Cash Out

Allakos Inc

Teladoc

The Fed's key interest rate target now stands at 3%-3.25%, way up from 0%-0.25% at the beginning of the year. That means, for all companies, borrowing money is becoming much more expensive.

3 Healthcare Stocks to Sell Before They Die

News for iBio Stock (IBIO)